Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2011

View Archived Issues

Bristol-Myers Squibb claims new tyrosine-protein kinase BTK inhibitors

New formylpeptide FPR2/ALX receptor agonists disclosed

Siena Biotech patents new inhibitors of hedgehog signaling

Vitae Pharmaceuticals describes novel 11-beta-HSD1 inhibitors

V-5 immunitor appears safe and effective in phase IIb tuberculosis trial

Study clarifies effect of amantadine on PD-associated dyskinesia

Clinical trial verifies mechanism of antisense oligonucleotide LY-2181308

New ligands claimed of nicotinic acetylcholine alpha7/alpha4beta2 receptors

FDA extends label for Actemra

First-in-human study evaluates multikinase inhibitor 4SC-203

Xoma reports interim phase II data on XOMA-052 in type 2 diabetes

Cyclacel provides overview of 2010 and outlines objectives for 2011

Amgen and Xencor to jointly develop XmAb-5871

DBV Technologies raises funds to support development of Viaskin Peanut

Pharmasset reports on two programs in HCV infection

Apaziquone enters Japanese phase I trial in bladder cancer

Teva Pharma adds women's health portfolio with acquisition of Theramex

Russian government clears Cel-Sci 's phase III Multikine trial in head and neck cancer

Spectrum Pharma and Viropro sign agreement for development of rituximab biosimilar

Opexa prepares pivotal phase III trial of Tovaxin in MS

Ziopharm Oncology and Intrexon partner to develop DNA-based oncology therapeutics

Inhibition of HSP 90 is efficacious in MET-amplified tumor cells

Ardea's phase IIb RDEA-594 trial in allopurinol-refractory gout meets endpoints

Zafgen reports topline phase Ib data on ZGN-433 in obesity

New PET tracer [76Br]-MBBG shows promise in imaging NET-positive tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...